nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

01.12.2010 | Article

Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains

verfasst von: V. Pliaka, Z. Kyriakopoulou, D. Tsakogiannis, I. G. A. Ruether, C. Gartzonika, S. Levidiotou-Stefanou, A. Krikelis, P. Markoulatos

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Attenuated strains of Sabin poliovirus vaccine replicate in the human gut and, in rare cases, may cause vaccine-associated paralytic poliomyelitis (VAPP). The genetic instability of Sabin strains constitutes one of the main causes of VAPP, a disease that is most frequently associated with type 3 and type 2 Sabin strains, and more rarely with type 1 Sabin strains. In the present study, the growth phenotype of eight oral poliovirus vaccine (OPV) isolates (two non-recombinants and six recombinants), as well as of Sabin vaccine strains, was evaluated using two different assays, the reproductive capacity at different temperatures (Rct) test and the one-step growth curve test in Hep-2 cells at two different temperatures (37°C and 40°C). The growth phenotype of isolates was correlated with genomic modifications in order to identify the determinants and mechanisms of reversion towards neurovirulence. All of the recombinant OPV isolates showed a thermoresistant phenotype in the Rct test. Moreover, both recombinant Sabin-3 isolates showed significantly higher viral yield than Sabin 3 vaccine strain at 37°C and 40°C in the one-step growth curve test. All of the OPV isolates displayed mutations at specific sites of the viral genome, which are associated with the attenuated and temperature-sensitive phenotype of Sabin strains. The results showed that both mutations and recombination events could affect the phenotype traits of Sabin derivatives and may lead to the reversion of vaccinal strains to neurovirulent ones. The use of phenotypic markers along with the genomic analysis may shed additional light on the molecular determinants of the reversed neurovirulent phenotype of Sabin derivatives.

Wimmer E, Hellen CUT, Cao X (1993) Genetics of poliovirus. Annu Rev Genet 27:353–436CrossRefPubMed

Pilipenko EV, Blinov VM, Romanova LI, Sinyakov AN, Maslova SV, Agol VI (1989) Conserved structural domains in the 5′-untranslated region of picornaviral genomes: an analysis of the segment controlling translation and neurovirulence. Virology 168:201–209CrossRefPubMed

Skinner MA, Racaniello VR, Dunn G, Cooper J, Minor PD, Almond JW (1989) New model for the secondary structure of the 5′ non-coding RNA of poliovirus is supported by biochemical and genetic data that also show that RNA secondary structure is important in neurovirulence. J Mol Biol 207:379–392CrossRefPubMed

Pelletier J, Kaplan G, Racaniello VR, Sonenberg N (1988) Cap-independent translation of poliovirus mRNA is conferred by sequence elements within the 5′ noncoding region. Mol Cell Biol 8:1103–1112PubMed

Sabin AB, Boulger LR (1973) History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand 1:115–118CrossRef

Christodoulou C, Colbere-Garapin F, Macadam A, Taffs LF, Marsden S, Minor P, Horaud F (1990) Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J Virol 64:4922–4929PubMed

Macadam AJ, Arnold C, Howlett J, John A, Marsden S, Taffs F, Reeve P, Hamada N, Wareham K, Almond J, Cammack N, Minor PD (1989) Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology 172:408–414CrossRefPubMed

Macadam AJ, Pollard SR, Ferguson G, Dunn G, Skuce R, Almond JW, Minor PD (1991) The 5′ noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology 181:451–458CrossRefPubMed

Bouchard MJ, Lam DH, Racaniello VR (1995) Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J Virol 69:4972–4978PubMed

10.

Georgescu MM, Tardy-Panit M, Guillot S, Crainic R, Delpeyroux F (1995) Mapping of mutations contributing to the temperature sensitivity of the Sabin 1 vaccine strain of poliovirus. J Virol 69:5278–5286PubMed

11.

Kawamura N, Kohara M, Abe S, Komatsu T, Tago K, Arita M, Nomoto A (1989) Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol 63:1302–1309PubMed

12.

Omata T, Kohara M, Kuge S, Komatsu T, Abe S, Semler BL, Kameda A, Itoh H, Arita M, Wimmer E, Nomoto A (1986) Genetic analysis of the attenuation phenotype of poliovirus type 1. J Virol 58:348–358PubMed

13.

Tardy-Panit M, Blondel B, Martin A, Tekaia F, Horaud F, Delpeyroux F (1993) A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice. J Virol 67:4630–4638PubMed

14.

Otelea D, Guillot S, Furione M, Combiescu AA, Balanant J, Candrea A, Crainic R (1993) Genomic modifications in naturally occurring neurovirulent revertants of Sabin 1 polioviruses. Dev Biol Stand 78:33–38PubMed

15.

Ogra PL, Faden HS, Abraham R, Duffy LC, Sun M, Minor PD (1991) Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J Infect Dis 164(1):191–194PubMed

16.

Minor PD, Dunn G, Evans DM, Magrath DI, John A, Howlett J, Phillips A, Westrop G, Wareham K, Almond JW, Hogle JM (1989) The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3. J Gen Virol 70:1117–1123CrossRefPubMed

17.

Westrop GD, Wareham KA, Evans DM, Dunn G, Minor PD, Magrath DI, Taffs F, Marsden S, Skinner MA, Schild GC, Almond JW (1989) Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol 63:1338–1344PubMed

18.

Guest S, Pilipenko E, Sharma K, Chumakov K, Roos RP (2004) Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3. J Virol 78:11097–11107CrossRefPubMed

19.

Gutiérrez AL, Denova-Ocampo M, Racaniello VR, del Angel RM (1997) Attenuating mutations in the poliovirus 5′ untranslated region alter its interaction with polypyrimidine tract-binding protein. J Virol 71:3826–3833PubMed

20.

Evans DM, Dunn G, Minor PD, Schild GC, Cann AJ, Stanway G, Almond JW, Currey K, Maizel JV Jr (1985) Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 314(6011):548–550CrossRefPubMed

21.

Gnanashanmugam D, Falkovitz-Halpern MS, Dodge A, Fang M, Wong LJ, Esparza M, Hammon R, Rivas-Merelles EE, Santos JI, Maldonado Y (2007) Shedding and reversion of oral polio vaccine type 3 in Mexican vaccinees: comparison of mutant analysis by PCR and enzyme cleavage to a real-time PCR assay. J Clin Microbiol 45(8):2419–2425CrossRefPubMed

22.

Martinez CV, Old MO, Kwock DK, Khan SS, Garcia JJ, Chan CS, Webster R, Falkovitz-Halpern MS, Maldonado YA (2004) Shedding of sabin poliovirus Type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine. J Infect Dis 190(2):409–416CrossRefPubMed

23.

Centers for Disease Control and Prevention (CDC) (1997) Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 46:1–25

24.

Furione M, Guillot S, Otelea D, Balanant J, Candrea A, Crainic R (1993) Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology 196:199–208CrossRefPubMed

25.

Georgescu MM, Balanant J, Macadam A, Otelea D, Combiescu M, Combiescu AA, Crainic R, Delpeyroux F (1997) Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J Virol 71:7758–7768PubMed

26.

Cherkasova EA, Yakovenko ML, Rezapkin GV, Korotkova EA, Ivanova OE, Eremeeva TP, Krasnoproshina LI, Romanenkova NI, Rozaeva NR, Sirota L, Agol VI, Chumakov KM (2005) Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine. J Virol 79:1062–1070CrossRefPubMed

27.

Yakovenko ML, Korotkova EA, Ivanova OE, Eremeeva TP, Samoilovich E, Uhova I, Gavrilin GV, Agol VI (2009) Evolution of the Sabin vaccine into pathogenic derivatives without appreciable changes in antigenic properties: need for improvement of current poliovirus surveillance. J Virol 83(7):3402–3406CrossRefPubMed

28.

Georgopoulou A, Markoulatos P, Spyrou N, Vamvakopoulos NC (2000) Improved genotyping vaccine and wild-type poliovirus strains by restriction fragment length polymorphism analysis: clinical diagnostic implications. J Clin Microbiol 38:4337–4342PubMed

29.

Balanant J, Guillot S, Candrea A, Delpeyroux F, Crainic R (1991) The natural genomic variability of poliovirus analyzed by a restriction fragment length polymorphism assay. Virology 184:645–654CrossRefPubMed

30.

Mulders MN, Reimerink JH, Stenvik M, Alaeddinoglu I, van der Avoort HG, Hovi T, Koopmans MP (1999) A Sabin vaccine-derived field isolate of poliovirus type 1 displaying aberrant phenotypic and genetic features, including a deletion in antigenic site 1. J Gen Virol 80:907–916PubMed

31.

Dedepsidis E, Karakasiliotis I, Paximadi E, Kyriakopoulou Z, Komiotis D, Markoulatos P (2006) Detection of unusual mutation within the VP1 region of different re-isolates of poliovirus Sabin vaccine. Virus Genes 33:183–191CrossRefPubMed

32.

Karakasiliotis I, Markoulatos P, Katsorchis T (2004) Site analysis of recombinant and mutant poliovirus isolates of Sabin origin from patients and from vaccinees. Mol Cell Probes 18:103–109CrossRefPubMed

33.

Paximadi E, Karakasiliotis I, Mamuris Z, Stathopoulos C, Krikelis V, Markoulatos P (2006) Genomic analysis of recombinant sabin clinical isolates. Virus Genes 32:203–210CrossRefPubMed

34.

Nakano JH, Hatch MH, Thieme ML, Nottay B (1978) Parameters for differentiating vaccine-derived and wild poliovirus strains. Prog Med Virol 24:178–206PubMed

35.

Malnou CE, Pöyry TA, Jackson RJ, Kean KM (2002) Poliovirus internal ribosome entry segment structure alterations that specifically affect function in neuronal cells: molecular genetic analysis. J Virol 76(21):10617–10626CrossRefPubMed

36.

Rezapkin GV, Chumakov KM, Lu Z, Ran Y, Dragunsky EM, Levenbook IS (1994) Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine. Virology 202:370–378CrossRefPubMed

37.

Cherkasova EA, Korotkova EA, Yakovenko ML, Ivanova OE, Eremeeva TP, Chumakov KM, Agol VI (2002) Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J Virol 76:6791–6799CrossRefPubMed

38.

Minor PD, Ferguson M, Evans DM, Almond JW, Icenogle JP (1986) Antigenic structure of polioviruses of serotypes 1, 2 and 3. J Gen Virol 67:1283–1291CrossRefPubMed

39.

Harber J, Bernhardt G, Lu HH, Sgro JY, Wimmer E (1995) Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor. Virology 214:559–570CrossRefPubMed

40.

He Y, Bowman VD, Mueller S, Bator CM, Bella J, Peng X, Baker TS, Wimmer E, Kuhn RJ, Rossmann MG (2000) Interaction of the poliovirus receptor with poliovirus. Proc Natl Acad Sci USA 97:79–84CrossRefPubMed

41.

Muzychenko AR, Lipskaya GYu, Maslova SV, Svitkin YV, Pilipenko EV, Nottay BK, Kew OM, Agol VI (1991) Coupled mutations in the 5′-untranslated region of the Sabin poliovirus strains during in vivo passages: structural and functional implications. Virus Res 21:111–122CrossRefPubMed

42.

Macadam AJ, Pollard SR, Ferguson G, Skuce R, Wood D, Almond JW, Minor PD (1993) Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 192:18–26CrossRefPubMed

43.

Minor PD, Macadam AJ, Stone DM, Almond JW (1993) Genetic basis of attenuation of the Sabin oral poliovirus vaccines. Biologicals 21:357–363CrossRefPubMed

44.

Guillot S, Otelea D, Delpeyroux F, Crainic R (1994) Point mutations involved in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction. Vaccine 12:503–507CrossRefPubMed

45.

Georgescu MM, Delpeyroux F, Tardy-Panit M, Balanant J, Combiescu M, Combiescu AA, Guillot S, Crainic R (1994) High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis. J Virol 68:8089–8101PubMed

46.

Friedrich F (1996) Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees. Acta Virol 40:157–170PubMed

47.

Equestre M, Genovese D, Cavalieri F, Fiore L, Santoro R, Perez Bercoff R (1991) Identification of a consistent pattern of mutations in neurovirulent variants derived from the sabin vaccine strain of poliovirus type 2. J Virol 65:2707–2710PubMed

48.

La Monica N, Almond JW, Racaniello VR (1987) A mouse model for poliovirus neurovirulence identifies mutations that attenuate the virus for humans. J Virol 61:2917–2920PubMed

49.

La Monica N, Racaniello VR (1989) Differences in replication of attenuated and neurovirulent polioviruses in human neuroblastoma cell line SH-SY5Y. J Virol 63:2357–2360PubMed

50.

Chumakov KM, Powers LB, Noonan KE, Roninson IB, Levenbook IS (1991) Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci USA 88:199–203CrossRefPubMed

51.

Pliaka V, Dedepsidis E, Kyriakopoulou Z, Papadopoulou I, Levidiotou S, Markoulatos P (2007) Use of mutational pattern in 5′-NCR and VP1 regions of polioviruses for molecular diagnosis. Mol Cell Probes 21:267–275CrossRefPubMed

52.

Pliaka V, Dedepsidis E, Kyriakopoulou Z, Papadi G, Tsakogiannis D, Pratti A, Levidiotou-Stefanou S, Markoulatos P (2010) Growth kinetic analysis of bi-recombinant poliovirus vaccine strains. Virus Genes 40(2):200–211CrossRefPubMed

53.

Weeks-Levy C, Tatem JM, DiMichele SJ, Waterfield W, Georgiu AF, Mento SJ (1991) Identification and characterization of a new base substitution in the vaccine strain of Sabin 3 poliovirus. Virology 185:934–937CrossRefPubMed

54.

Tatem JM, Weeks-Levy C, Georgiu A, DiMichele SJ, Gorgacz EJ, Racaniello VR, Cano FR, Mento SJ (1992) A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating. J Virol 66:3194–3197PubMed

55.

Mento SJ, Weeks-Levy C, Tatem JM, Gorgacz EJ, Waterfield WF (1993) Significance of a newly identified attenuating mutation in Sabin 3 oral poliovirus vaccine. Dev Biol Stand 78:93–100PubMed

56.

Fricks CE, Hogle JM (1990) Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding. J Virol 64:1934–1945PubMed

57.

Martin A, Benichou D, Couderc T, Hogle JM, Wychowski C, Van der Werf S, Girard M (1991) Use of type 1/type 2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model. Virology 180:648–658CrossRefPubMed

58.

McGoldrick A, Macadam AJ, Dunn G, Rowe A, Burlison J, Minor PD, Meredith J, Evans DJ, Almond JW (1995) Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus. J Virol 69:7601–7605PubMed

59.

Paul AV, Rieder E, Kim DW, van Boom JH, Wimmer E (2000) Identification of an RNA hairpin in poliovirus RNA that serves as the primary template in the in vitro uridylylation of VPg. J Virol 74:10359–10370CrossRefPubMed

60.

Rieder E, Paul AV, Kim DW, van Boom JH, Wimmer E (2000) Genetic and biochemical studies of poliovirus cis-acting replication element cre in relation to VPg uridylylation. J Virol 74:10371–10380CrossRefPubMed

61.

Martín J, Odoom K, Tuite G, Dunn G, Hopewell N, Cooper G, Fitzharris C, Butler K, Hall WW, Minor PD (2004) Long-term excretion of vaccine-derived poliovirus by a healthy child. J Virol 78:13839–13847CrossRefPubMed

62.

Horie H, Yoshida H, Matsuura K, Miyazawa M, Wakabayashi K, Nomoto A, Hashizume S (2002) Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan. J Med Virol 68:445–451CrossRefPubMed

63.

Cello J, Toyoda H, Dejesus N, Dobrikova EY, Gromeier M, Wimmer E (2008) Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses. J Med Virol 80:352–359CrossRefPubMed

64.

Malnou CE, Werner A, Borman AM, Westhof E, Kean KM (2004) Effects of vaccine strain mutations in domain V of the internal ribosome entry segment compared in the wild type poliovirus type 1 context. J Biol Chem 279:10261–10269CrossRefPubMed

65.

De Jesus N, Franco D, Paul A, Wimmer E, Cello J (2005) Mutation of a single conserved nucleotide between the cloverleaf and internal ribosome entry site attenuates poliovirus neurovirulence. J Virol 79:14235–14243CrossRefPubMed

66.

Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR (1992) Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 14:568–579PubMed

67.

Strebel PM, Aubert-Combiescu A, Ion-Nedelcu N, Biberi-Moroeanu S, Combiescu M, Sutter RW, Kew OM, Pallansch MA, Patriarca PA, Cochi SL (1994) Paralytic poliomyelitis in Romania, 1984–1992. Evidence for a high risk of vaccine-associated disease and reintroduction of wild-virus infection. Am J Epidemiol 140:1111–1124PubMed

68.

Cuervo NS, Guillot S, Romanenkova N, Combiescu M, Aubert-Combiescu A, Seghier M, Caro V, Crainic R, Delpeyroux F (2001) Genomic features of intertypic recombinant sabin poliovirus strains excreted by primary vaccinees. J Virol 75:5740–5751CrossRefPubMed

69.

Driesel G, Diedrich S, Kunkel U, Schreier E (1995) Vaccine-associated cases of poliomyelitis over a 30 year period in East Germany. Eur J Epidemiol 11:647–654CrossRefPubMed

70.

Gavrilin GV, Cherkasova EA, Lipskaya GY, Kew OM, Agol VI (2000) Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model. J Virol 74:7381–7390CrossRefPubMed

71.

Savolainen-Kopra C, Samoilovich E, Kahelin H, Hiekka AK, Hovi T, Roivainen M (2009) Comparison of poliovirus recombinants: accumulation of point mutations provides further advantages. J Gen Virol 90(Pt 8):1859–1868CrossRefPubMed

72.

Friedrich F, Filippis AM, Ferreira FC, Schatzmayr HG, Da-Silva EE (1995) Genomic characterization of type 2 polioviruses isolated from vaccine-associated cases in Brazil. Braz J Med Biol Res 28(7):733–742PubMed

73.

Blomqvist S, Bruu AL, Stenvik M, Hovi T (2003) Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1. J Gen Virol 84:573–580CrossRefPubMed

74.

Martín J, Samoilovich E, Dunn G, Lackenby A, Feldman E, Heath A, Svirchevskaya E, Cooper G, Yermalovich M, Minor PD (2002) Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis. J Virol 76:10921–10928CrossRefPubMed

75.

Paximadi E, Karakasiliotis I, Bolanaki E, Krikelis A, Markoulatos P (2007) Vaccine derived bi- and multi-recombinant Sabin strains. Virus Genes 35:541–548CrossRefPubMed

Titel: Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains
verfasst von: V. Pliaka
Z. Kyriakopoulou
D. Tsakogiannis
I. G. A. Ruether
C. Gartzonika
S. Levidiotou-Stefanou
A. Krikelis
P. Markoulatos
Publikationsdatum: 01.12.2010
Verlag: Springer-Verlag
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 12/2010
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-010-1033-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2010

Virulence factors profile of drug-resistant Escherichia coli isolates from urinary tract infections in Punjab, Pakistan

Stronger correlation between antibiotic use and the incidence of Clostridium difficile determined by culture results instead of faecal toxin detection only

Risk of acquiring tick-borne infections in forestry workers from Lazio, Italy

Extremely elevated erythrocyte sedimentation rates (ESRs) in Legionnaires’ disease

Relevance of lower airway bacterial colonization, airway inflammation, and pulmonary function in the stable stage of chronic obstructive pulmonary disease

The importance of a judicious and early empiric choice of antimicrobial for methicillin-resistant Staphylococcus aureus bacteraemia

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin